All In Biotech

Drug Trial Radar · NCT06581198

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

179

Planned (sponsor's estimate)

Start

Sep 4, 2024

Primary completion

Feb 14, 2028

Study completion Feb 6, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Conditions

  • Lupus Erythematosus, Systemic
  • Lupus Nephritis

Interventions

  • rapcabtagene autoleucelBiological

    single infusion of rapcabtagene autoleucel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of rapcabtagene autoleucelTime frame: Week 24, Week 52

Locations

107 sites in 26 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama

  • Loma Linda University

    San Bernardino, California

  • UCSF

    San Francisco, California

  • Sutter Health Network

    San Pablo, California

  • Ann and Robert H Lurie Childs Hosp

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • University Of Iowa

    Iowa City, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • WA Uni School Of Med

    St Louis, Missouri

  • Duke Clinical Research Institute

    Durham, North Carolina

  • James Cancer Hospital

    Columbus, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • Houston Methodist Hospital

    Houston, Texas

  • Univ Of TX MD Anderson CC

    Houston, Texas

  • LDS Hospital

    Salt Lake City, Utah

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Olomouc, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Aarhus N, Denmark

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Paris, France

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.